Attention Deficit Hyperactive Disorder

Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention deficit hyperactivity disorder (ADHD) program in addition to a follow-up candidate soon to enter human trials and a...

Cantor Fitzgerald's Maria Goldstein initiated Alcobra Ltd(NASDAQ: ADHD) at Buy with a price target of $16.00. Goldstein believes Alcobra's MDX, a non-stimulant-based drug to treat ADHD, has "an opportunity to achieve a statistically significant result with substantive hanged incorporated in the...